International Meeting of the Society of Cardiac Robotics

Stereoscopic receiving the St. Louis Mayor Innovation Award for

Street. LEWIs, October 3, 2022 (GLOBE NEWSWIRE) — Stereotactic (NYSE: STXS), the leading and global leader in minimally invasive endovascular surgical robotics, today announced that it has received the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones. This honor reflects stereoscopic regional leadership in developing advanced technologies that have a positive impact on society.

Stereotactic robotic magnetic navigation technology is known for providing the robotic accuracy and safety benefits of minimally invasive procedures to treat arrhythmias. Tens of millions of people worldwide have arrhythmias — abnormal heart rhythms that result when the heart beats too fast, too slowly, or in an irregular pattern. Hundreds of physicians have used stereotaxic robotic systems to treat more than 100,000 patients globally. Multiple clinical publications have demonstrated that the technology supports improved procedural safety and enables clinicians to treat even the most difficult arrhythmias in patients with few other alternatives.

In recent years, stereoscopy has greatly increased its investment in innovation, and the company spends more than $10 million annually on research and development activities. These activities have supported the development of new robotic surgery platforms, intravascular instruments, and information solutions for the operating room. The guiding principles that motivate all innovation efforts in stereotaxic are to improve patient care, enhance the clinician experience, and increase the widespread accessibility and affordability of robotics.

Earlier this year, Stereotaxis opened its 45,000-square-foot global headquarters in downtown St. Louis. Located in the renovated historic Globe Building in the growing downtown area of ​​North Urban Insight in St. Louis, the company’s new global headquarters is an integrated facility that provides high-tech research and development, advanced manufacturing and distribution space for the company’s pipeline of cutting-edge robotic surgery technologies.

“Hyreotaxis has made significant progress in our mission to make the accuracy and safety of robots accessible to patients at scale,” said David Fischel, Stereotaxis Chairman and CEO. “We are proud to receive this award. It is a reflection of the creativity and efforts of the many talented individuals on our team in St. Louis and around the world, as well as the broader community of clinicians and partners driving the development of our technology.”

about stereotaxic
Stereotactic is the world leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and to perform endovascular procedures. Its mission is to discover, develop and deliver automated systems, tools and information solutions to the interventional laboratory. These innovations help clinicians deliver unprecedented patient care with robotic accuracy and safety, expand access to minimally invasive treatment, and enhance productivity, connectivity, and intelligence in the operating room. Stereotactic technology has been used to treat more than 100,000 patients across the United States, Europe, Asia and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute “forward-looking” statements, and usually contain the words “believes,” “estimates,” “projects,” “expects,” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, market acceptance of the Company’s products, the impact of global economic conditions on customers’ ability and willingness to purchase technology, competitive factors and changes resulting from policy Health care, dependence on outside vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no guarantee that the Company will recognize revenue related to purchase orders and other commitments because some of these purchase orders and other commitments are subject to possibilities beyond the Company’s control and may be revised, modified, delayed or canceled.

Investor contacts:
David L Fishel
Chairman and CEO

Kimberly Perry
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

Media contact:
Bethany Schlutter
Marketing and Communications Manager
314-678-6213
B.Schluter@Stereotaxis.com

#Stereoscopic #receiving #Louis #Mayor #Innovation #Award

Leave a Comment

Your email address will not be published. Required fields are marked *